UBS: InnoCare Pharma (09969.HK) and Eli Lilly (LLY.US) Reach Collaboration on Innovative Target Project; View Positive

Zhitong Finance APP has learned that UBS issued a research report maintaining a "Buy" rating and a target price of HK$21.8 for InnoCare Pharma (09969.HK). InnoCare Pharma has reached a collaboration with Eli Lilly (LLY.US) to discover and develop up to 5 innovative target projects. The bank views this positively, considering it recognition of the company's R&D capabilities.